PT - JOURNAL ARTICLE AU - KODAMA, HIROYUKI AU - KADOWAKI, SHIGENORI AU - NAKAZAWA, TAIKO AU - MATSUBARA, YUKI AU - NARITA, YUKIYA AU - HONDA, KAZUNORI AU - MASUISHI, TOSHIKI AU - TANIGUCHI, HIROYA AU - ANDO, MASASHI AU - KOIDE, YUTARO AU - TACHIBANA, HIROYUKI AU - KODAIRA, TAKESHI AU - SAWABE, MICHI AU - TERADA, HOSHINO AU - BEPPU, SHINTARO AU - NISHIKAWA, DAISUKE AU - SUZUKI, HIDENORI AU - HANAI, NOBUHIRO AU - MURO, KEI TI - Safety and Efficacy of Gemcitabine Plus Cisplatin Against Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective Study AID - 10.21873/anticanres.16918 DP - 2024 Mar 01 TA - Anticancer Research PG - 1227--1232 VI - 44 IP - 3 4099 - http://ar.iiarjournals.org/content/44/3/1227.short 4100 - http://ar.iiarjournals.org/content/44/3/1227.full SO - Anticancer Res2024 Mar 01; 44 AB - Background/Aim: Although gemcitabine plus cisplatin (GC) prolongs survival in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) compared with fluorouracil plus cisplatin, no study has evaluated the efficacy and safety of GC in nonendemic regions, including Japan, yet. Therefore, we assessed the safety and efficacy of GC in Japanese patients with R/M NPC. Patients and Methods: We retrospectively reviewed patients with R/M NPC who received GC treatment at the Aichi Cancer Center Hospital from January 2017 to March 2020. The main eligibility criteria were histologically confirmed NPC, Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2, and locally recurrent disease unsuitable for local treatment or metastatic disease. The regimen was administered every 3 weeks (gemcitabine, 1,000 mg/m2 on days 1 and 8; cisplatin, 80 mg/m2 on day 1). Results: Fourteen patients (median age, 58 years) were included in the study. Two patients had an ECOG PS of 2 and 11 exhibited nonkeratinizing histology. Of the eight patients with measurable lesions, one exhibited complete response and seven exhibited partial response, with an objective response rate of 75%. Median progression-free survival and overall survival were 7.7 and 24.2 months, respectively. Common grade 3 or 4 adverse events included neutropenia (64%), thrombocytopenia (14%), and febrile neutropenia (14%). The median relative dose intensity of gemcitabine and cisplatin was 62% and 60%, respectively. No treatment-related deaths occurred. Conclusion: The GC regimen demonstrates promising activity and is tolerable in Japanese patients with R/M NPC.